Log In
BCIQ
Print this Print this
 

Vantas, histrelin

  Manage Alerts
Collapse Summary General Information
Company Endo International plc
DescriptionImplant to deliver synthetic nonapeptide agonist of GnRH/LHRH receptor over a 12-month period
Molecular Target GnRH/LHRH receptor
Mechanism of ActionGnRH/LHRH receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationProstate cancer
Indication DetailsTreat advanced prostate cancer; Treat metastatic prostate cancer; Treat prostate cancer
Regulatory Designation
PartnerOrion Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today